ClinicalTrials.gg
RecruitingNCT05223413RESILIENCEUpdated Oct 29, 2026

REmote iSchemic condItioning in Lymphoma PatIents REceiving ANthraCyclinEs

An interventional study of RIPC and Simulated RIPC (Sham) in Anthracycline-induced Cardiac Toxicity and Lymphoma, sponsored by Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III. Recruiting at 24 sites in 6 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jan 2022; still recruiting 4 years 10 months later.
Updated Oct 29, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
608
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 143 studies in Lymphoma with a site in Spain — 25 open to participants now, 43 under way, 10 of them phase 3. Lymphoma · Spain.

Planned enrollment
12th of 134
608 · median 111
Started
2022
with 11 others
No phase
4 of 143
3 open now
Primary completion
2027-06
later than 22 of 42 live
Registered
116th of 143
by date

Among the 143 studies in Lymphoma with a site in Spain, this one is the 12th largest by planned enrollment of the 134 interventional ones that give a count, is one of 12 that started in 2022, is one of 4 with no phase, reaches primary completion later than 22 of the 42 other live ones, and was the 116th registered.

Lymphoma

3,020 studies on the registry are indexed under Lymphoma; 434 are open to participants now.

Browse Lymphoma studies →

Open to participants now

25 of the 143 studies in Lymphoma with a site in Spain are open now. Recruiting first, the newest first:

19 more — sign in →

All 25 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 143 studies in Lymphoma with a site in Spain, or all of them as a file.
02

Study summary

Multinational, prospective, proof of concept phase II, double-blinded, sham-controlled, randomized clinical trial (RCT) to evaluate the efficacy and safety of Remote Ischaemic PreConditioning (RIPC) in Lymphoma patients receiving anthracyclines.

Read the detailed description

Multinational, prospective, proof of concept phase II, double-blinded, sham-controlled, randomized clinical trial (RCT) to evaluate the efficacy and safety of Remote Ischaemic PreConditioning (RIPC) in lymphoma patients receiving anthracyclines. Patients scheduled to undergo ≥5 chemotherapy cycles will be eligible. Patients fulfilling all inclusion and no exclusion criteria will be enrolled and undergo baseline Cardiac Magnetic Baseline (CMR), and high sensitivity troponin (hsTn) and NT-proBNP blood test. Patients with confirmed LVEF >40% by CMR will be randomized 1:1 to RIPC vs simulated RIPC (Sham). After the third chemotherapy cycle, a second CMR+ hsTn/ NT-proBNP will be performed for the validation of the early marker of cardiotoxicity. A third hsTn/ NT-proBNP blood test will be performed in the last chemotherapy cycle. Nine weeks after finishing chemotherapy, a last CMR+ hsTn/ NT-proBNP will be performed. Patients will be followed-up for clinical events at 6, 12, 18, 30 and 42 months until the last patient undergoes the final CMR. When the last patient undergoes the third CMR, the follow-up will be closed. The median follow-up estimation for clinical endpoints is 36 months (range: 6 to 60 months).

03

Conditions studied

  • Anthracycline-induced Cardiac Toxicity
  • Lymphoma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

≥18 years old NHL, HL or breast cancer diagnosis Scheduled to undergo chemotherapy including ≥ 240 mg/k2 cumulative dose of anthracyclines.

Pre-chemo >40% on screening echocardiography.

Presence of ≥1 of the following risk factors for developing cardiotoxicity:

Previous coronary artery disease (any of the following):

Previous coronary revascularisation (PCI or CABG) or Medical history of previous significant nonrevascularized coronary stenosis Previous Acute Coronary Syndrome / Acute Myocardial Infarction with a LVEF > 40 LVEF 41-54% Age ≥ 65 years old Previous diagnosis of arterial hypertension (with or without treatment) Chronic kidney disease (estimated \<60ml/min/1.73m2) Current or former smoker. Obesity (≥30 kg/m2) LVH on screening echocardiography (LV thickness ≥12mm). High alcohol intake (≥21 alcoholic beverages per week) Sinus rhythm on screening Previous diagnosis of diabetes (except those treated with sulfonylureas or those with neuropathy) Previous non-anthracycline-based chemotherapy Signed Form (ICF)

Exclusion criteria

Exclusion Criteria:

  • History of any of the following diseases:

    • Any cancer who received anthracyclines treatment before the index episode.
    • Previous clinical diagnosis of heart failure.
    • Permanent atrial fibrillation (AF).
    • Severe valvular or sub-valvular heart disease.
    • Severe peripheral arterial disease in the upper extremities or arteriovenous (AV) shunt in the arm selected for RIPC.
  • Clinical diagnosis of diabetes neuropathy
  • for CMR:

    • Severe claustrophobia.
    • Any device which is known to threaten or pose hazard in all MR environments (http://www.mrisafety.com/).
    • Patients with implanted biomedical cardiac devices: pacemakers, ICDs or CRT.
  • Severe thrombocytopenia ( \<50,000/µL) on any blood test within the previous 3 months.
  • Patients participating in other clinical trials.
  • Impossibility to consent or undergo study follow-ups.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
608 participants (estimated)

Study arms

  • Active comparator
    Remote Ischemic Conditioning

    Remote Ischemic Conditioning (RIC): Patients will undergo weekly RIC during the entire span of the chemotherapy period. Each RIC session will include four cycles of 5 min blood pressure cuff inflation followed by 5 min deflation

    Device: RIPC

  • Sham comparator
    simulated RIPC (Sham)

    Control group (Sham): Patients will undergo weekly simulated RIC (sham) during the entire span of the chemotherapy period. Each sham session will include four cycles of 5 min blood pressure cuff inflation followed by 5 min deflation.

    Device: Simulated RIPC (Sham)

Interventions

  • DeviceRIPC

    The procedure will be performed by using an electric auto-control device (modified blood pressure monitor for remote ischemic conditioning, Seagull Healthcare Aps, Denmark) for Remote Ischemic Conditioning in the arm. During the inflation period, the blood pressure cuff is inflated to 200 mmHg to stop blood flow in the arm.

  • DeviceSimulated RIPC (Sham)

    The procedure will be performed by using an electric auto-control device (modified blood pressure monitor for remote ischemic conditioning, Seagull Healthcare Aps, Denmark) for Remote Ischemic Conditioning in the arm. During the inflation period, the blood pressure cuff is inflated to a low pressure not stopping blood flow in the arm.

06

What researchers measure

Primary outcomes

  1. Rate of anthracycline-induced cardiotoxicity events

    Cardiotoxicity event is defined as one of the following: * Drop in LVEF between study CMRs of ≥10 absolute points regardless the absolute value of follow- up ejection fraction (EF). * Drop in LVEF between study CMRs of ≥5 to \<10 absolute points with a follow-up EF value \<50% UNITS: absolute number of patients in each arm qualifying for cardiotoxicity event (i.e. each patient will be qualified at the end of the study as YES/NO).

    Time frame: 9 weeks after the last chemotherapy cycle (anticipated to be between 150 and 200 days from enrollment)

Secondary outcomes

  1. Primary efficacy endpoint: (RIC vs Sham) Absolute change in LVEF

    change in LVEF between baseline and any follow-up CMRs, whichever shows worse LVEF UNITS: LVEF is expressed as % LVEF= (LV end-diastolic volume - LV end-systolic volume) / LV end-systolic volume), %

    Time frame: 9 weeks after the last chemotherapy cycle (anticipated to be between 150 and 200 days from enrollment)

  2. Rate of tumor regression.

    Response to chemotherapy UNITS: absolute number of patients in each arm qualifying as responder or no responder (i.e. each patient will be qualified at the end of the study as YES/NO).

    Time frame: 9 weeks after the last chemotherapy cycle (anticipated to be between 150 and 200 days from enrollment)

  3. Change in Quality of Life-Haematological Malignancy Patient-Reported Outcome Measure questionnaire

    Haematological Malignancy Patient-Reported Outcome Measure (HM-PRO) questionnaire UNITS: absolute points in the questionnaire. minimum value 0 maximum value 84 the higher the total score, the better (greater the effect on a patient's QoL)

    Time frame: 9 weeks after the last chemotherapy cycle (anticipated to be between 150 and 200 days from enrollment)

  4. Change in Quality of Life-Euro Quality of Life-5 dimensions questionnaire

    Euro Quality of Life-5 dimensions (EuroQoL-5D) questionnaire: UNITS: absolute points in the questionnaire. minimum value 0 maximum value 100 the higher the total score, the better (greater the effect on a patient's QoL)

    Time frame: 9 weeks after the last chemotherapy cycle (anticipated to be between 150 and 200 days from enrollment)

  5. Change in Quality of Life-Kansas City Cardiomyopathy Questionnaire

    Kansas City Cardiomyopathy Questionnaire (KCCQ-12) UNITS: absolute points in the questionnaire. minimum value 0 maximum value 65 the higher the total score, the better (greater the effect on a patient's QoL)

    Time frame: 9 weeks after the last chemotherapy cycle (anticipated to be between 150 and 200 days from enrollment)

  6. Rate of Heart Failure Hospitalization

    Rate of Heart Failure Hospitalization UNITS: Absolute number of patients in each arm experiencing a heart failure hospitalization

    Time frame: 4-60 months

07

Study locations

21 of 24 sites recruiting
08

References and documents

Related links

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2022 (actual). Primary completion is estimated for Jun 2027, 65 months after the start.

Of 161 non-industry interventional studies with no phase under Lymphoma, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 87. This study's planned 65 months is above that.

Counting every sponsor, half of 170 studies reached it within 43 months; a quarter within 23 and three quarters within 87.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 29, 2026: primary completion Jun 2026 → Jun 2027 and completion Dec 2026 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2021
First posted
Feb 4, 2022
StartActual
Jan 18, 2022
Primary completionEst.
Jun 2027was Jun 2026
CompletionEst.
Dec 2027was Dec 2026
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jun 2026→Jun 2027
Oct 29, 2026
Study completion
Dec 2026→Dec 2027
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Primary completion Jun 2026→Jun 2027
    Study completion Dec 2026→Dec 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05223413
Lead sponsor
Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III
Collaborators
European Commission
Responsible party
Sponsor
First posted
Feb 4, 2022
Start date
Jan 18, 2022
Primary completion
Jun 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Oct 29, 2026

Study contacts

Borja Ibañez, MD PhD FESC
Contact
bibanez@cnic.es
914501200 ext. 4302
Noemi Escalera
Contact
nescalera@cnic.es
914501200 ext. 5401
Borja Ibañez, MD PhD FESC
principal investigator · CNIC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion